Every number.
Each number in the report, with the people it describes, the question behind it, where it sits in the source and what to keep in mind when using it.
SCAN 2025 numbers describe the 341 UK respondents, patients and carers, who chose to answer. Many were reached through Neuroendocrine Cancer UK. They are not rates for every UK patient. INCA's tables mark where a country differs from the global number, without naming the test; no test compares countries with each other. Global and Europe include the UK.
SCAN rows are rows in INCA's SCAN 2025 workbooks; numbers from Neuroendocrine Cancer UK's own survey give the question number instead. No number rests on fewer than 10 people.
1. The first screen
| Number | Value | Base | Question | Source and row | Compared with | Caveat |
|---|---|---|---|---|---|---|
| UK respondents to SCAN 2025, patients and carers | 341 | 341 UK respondents | Respondent base, United Kingdom column | SCAN 2025Row 11 | Global 2,764; Europe 1,566 | 93.3% are patients and 6.7% carers answering about the patient. They chose to answer, many reached through Neuroendocrine Cancer UK, so they are not a sample of all UK patients; Global and Europe totals include the UK. |
| Told they had at least one other condition before neuroendocrine cancer | 51.9% | 177 of 341 UK respondents | DA6, experience of getting a diagnosis: diagnosed with other conditions once, or more than once, before the NET diagnosis (codes 1 and 2). Cover question in plain words: before you were told you had neuroendocrine cancer, were you told you had something else? | SCAN 2025Row 588, 605 (DA7 base ÷ DA6 base); same as 589 + 591 | Global 40.0% (n=2,764); Europe 41.9% (n=1,566); Europe excluding the UK about 39.1% (n=1,225); Sweden 50.4% (n=121); New Zealand 49.1% (n=110); 2019 survey (different group of people) 53.0% (n=279) | Describes the 341 UK respondents, not all UK patients. Among the highest of the 17 countries compared, with Sweden and New Zealand close behind on smaller bases. INCA's tables do not mark the UK as different from the global number.Derived. |
2. The names it had first
| Number | Value | Base | Question | Source and row | Compared with | Caveat |
|---|---|---|---|---|---|---|
| Told they had something else more than once | 33.7% | 341 UK respondents | DA6, experience of getting a diagnosis: diagnosed with other conditions more than once before the NET diagnosis | SCAN 2025Row 589 | Global 25.3% (n=2,764); Europe 26.8% (n=1,566) | Describes the UK respondents who chose to answer, many reached through Neuroendocrine Cancer UK, not all UK patients. Global includes the UK. INCA's tables mark where a country differs from the global number, without naming the test. |
| Were told they had irritable bowel syndrome (IBS) | 41.8% | 177 UK respondents first told they had something else | DA7, conditions diagnosed before the NET diagnosis: IBS | SCAN 2025Row 622 (base 605) | Global 29.8% (n=1,106); Europe 32.3% (n=656) | Asked only of the 177 respondents first told they had something else. About 74 of them, roughly 22% of all 341, were told they had IBS. More than one answer was allowed. Not comparable with the IBS question in Neuroendocrine Cancer UK's own diagnosis survey. INCA's tables do not mark the UK as different from the global number.More than one answer allowed. |
| Were told they had gastritis or another digestive disorder | 30.5% | 177 UK respondents first told they had something else | DA7, conditions diagnosed before the NET diagnosis: gastritis or other digestive disorder | SCAN 2025Row 618 (base 605) | Global 33.8% (n=1,106) | Asked only of the 177 respondents first told they had something else, not all respondents. More than one answer allowed.More than one answer allowed. |
| Were told they had anxiety or a psychosomatic condition | 20.3% | 177 UK respondents first told they had something else | DA7, conditions diagnosed before the NET diagnosis: anxiety or psychosomatic-type condition | SCAN 2025Row 610 (base 605) | Global 20.0% (n=1,106); Europe 20.3% (n=656) | Asked only of the 177 respondents first told they had something else, not all respondents. More than one answer allowed.More than one answer allowed. |
| Were told it was the menopause | 11.9% | 177 UK respondents first told they had something else | DA7, conditions diagnosed before the NET diagnosis: menopause | SCAN 2025Row 624 (base 605) | Global 10.1% (n=1,106) | A share of all 177 respondents first told they had something else, men included, not only women. More than one answer allowed.More than one answer allowed. |
| Were told they had: Another condition not listed | 24.9% | 177 UK respondents first told they had something else | DA7, conditions diagnosed before the NET diagnosis: Another condition not listed | SCAN 2025Row 636 (base 605) | Global 19.9% (n=1,106) | Asked only of the 177 respondents first told they had something else, not all respondents. More than one answer allowed.More than one answer allowed. |
| Were told they had: Another cancer | 16.4% | 177 UK respondents first told they had something else | DA7, conditions diagnosed before the NET diagnosis: Another cancer | SCAN 2025Row 626 (base 605) | Global 17.9% (n=1,106) | Asked only of the 177 respondents first told they had something else, not all respondents. More than one answer allowed.More than one answer allowed. |
| Were told they had: Gall bladder dysfunction | 11.3% | 177 UK respondents first told they had something else | DA7, conditions diagnosed before the NET diagnosis: Gall bladder dysfunction | SCAN 2025Row 616 (base 605) | Global 11.0% (n=1,106) | Asked only of the 177 respondents first told they had something else, not all respondents. More than one answer allowed.More than one answer allowed. |
| Were told they had: Allergies | 10.2% | 177 UK respondents first told they had something else | DA7, conditions diagnosed before the NET diagnosis: Allergies | SCAN 2025Row 606 (base 605) | Global 11.4% (n=1,106) | Asked only of the 177 respondents first told they had something else, not all respondents. More than one answer allowed.More than one answer allowed. |
| Were told they had: Asthma | 7.9% | 177 UK respondents first told they had something else | DA7, conditions diagnosed before the NET diagnosis: Asthma | SCAN 2025Row 612 (base 605) | Global 7.5% (n=1,106) | Asked only of the 177 respondents first told they had something else, not all respondents. More than one answer allowed.More than one answer allowed. |
| Were told they had: Inflammatory bowel disease (Crohn's disease, ulcerative colitis) | 6.8% | 177 UK respondents first told they had something else | DA7, conditions diagnosed before the NET diagnosis: Inflammatory bowel disease (Crohn's disease, ulcerative colitis) | SCAN 2025Row 620 (base 605) | Global 8.8% (n=1,106) | Asked only of the 177 respondents first told they had something else, not all respondents. More than one answer allowed.More than one answer allowed. |
| After symptoms and tests, neuroendocrine cancer was the first diagnosis | 23.5% | 341 UK respondents | DA6, experience of getting a diagnosis: after initial symptoms and tests, NET was the first diagnosis received | SCAN 2025Row 593 | Global 28.6% (n=2,764); Europe 28.1% (n=1,566) | Describes the UK respondents who chose to answer, many reached through Neuroendocrine Cancer UK, not all UK patients. Global includes the UK. INCA's tables mark where a country differs from the global number, without naming the test. |
| Had no symptoms and were found during tests for something else | 22.6% | 341 UK respondents | DA6, experience of getting a diagnosis: no symptoms, found while testing for something else | SCAN 2025Row 595 | Global 29.3% (n=2,764); Europe 27.8% (n=1,566) | Describes the UK respondents who chose to answer, many reached through Neuroendocrine Cancer UK, not all UK patients. Global includes the UK. INCA's tables mark where a country differs from the global number, without naming the test. |
3. For some, years
| Number | Value | Base | Question | Source and row | Compared with | Caveat |
|---|---|---|---|---|---|---|
| Average years from first symptom to diagnosis | 4.7 years | 177 UK respondents first told they had something else | DA7.1, time from first symptom to NET diagnosis (asked only where DA6 is below 3) | SCAN 2025Row 725 (base 707) | Global 4.5 years (n=1,106); Europe 4.4 years (n=656) | Asked only of the 177 respondents first told they had something else, not all patients, and given to one decimal place. The method behind the average is not published. Global is 4.5 years and Europe 4.4. |
| Diagnosed within a year of first symptom | 23.7% | 177 UK respondents first told they had something else | DA7.1, time from first symptom to NET diagnosis: under 1 year | SCAN 2025Row 708 | Global 24.3% (n=1,106); Europe 24.5% (n=656) | Asked only of the 177 respondents first told they had something else, not all patients. The longest band counts everyone at 15 years or more. |
| Diagnosed in under three years (cumulative) | 42.4% | 177 UK respondents first told they had something else | DA7.1, time from first symptom to NET diagnosis: cumulative share below the 3-year band | SCAN 2025Row 708–714 (cumulative, derived) | Global 47.7% (n=1,106) | Asked only of the 177 respondents first told they had something else, not all patients. Worked out by adding the time bands together.Derived. |
| Diagnosed within three years, 3-year band included (cumulative) | 55.4% | 177 UK respondents first told they had something else | DA7.1, time from first symptom to NET diagnosis: cumulative share up to and including the 3-year band | SCAN 2025Row 708–714 (cumulative, derived) | Global 57.4% (n=1,106) | Asked only of the 177 respondents first told they had something else, not all patients. Adds the time bands up to and including three years; the middle answer falls in the three-year band for both the UK and Global.Derived. |
| Six years or more from first symptom to diagnosis | 29.9% | 177 UK respondents first told they had something else | DA7.1, time from first symptom to NET diagnosis: bands 6–9, 10–14 and 15 | SCAN 2025Row 718–722 (summed) | Global 28.2% (n=1,106) | Asked only of the 177 respondents first told they had something else, about 53 people. Worked out by adding the bands from six years up, with the top band read as 15 years or more.Derived. |
| Ten years or more from first symptom to diagnosis | 14.1% | 177 UK respondents first told they had something else | DA7.1, time from first symptom to NET diagnosis: bands 10–14 and 15 | SCAN 2025Row 720–722 (summed) | Global 15.8% (n=1,106) | Asked only of the 177 respondents first told they had something else, not all patients. Worked out by adding the bands from ten years up, with the top band read as 15 years or more.Derived. |
| Five-year survival, small intestine NET found at stage 1 | 86% | people with small intestine NET in England, 2012–2018 (cancer registry) | Five-year survival, small intestine NET, stage 1 at diagnosis (unadjusted) | White et al. (2022), The Lancet Regional Health – Europe 23:100510Row Supplementary Table 4 | – | Not from SCAN: cancer registry data for England, 2012–2018, from a peer-reviewed study. It shows that the stage at diagnosis is linked to survival; it does not measure delay itself. |
| Five-year survival, small intestine NET found at stage 4 | 43% | people with small intestine NET in England, 2012–2018 (cancer registry) | Five-year survival, small intestine NET, stage 4 at diagnosis (unadjusted) | White et al. (2022), The Lancet Regional Health – Europe 23:100510Row Supplementary Table 4 | – | Not from SCAN: cancer registry data for England, 2012–2018, from a peer-reviewed study. It shows that the stage at diagnosis is linked to survival; it does not measure delay itself. |
| Five-year survival, pancreatic NET found at stage 1 | 87% | people with pancreatic NET in England, 2012–2018 (cancer registry) | Five-year survival, pancreatic NET, stage 1 at diagnosis (unadjusted) | White et al. (2022), The Lancet Regional Health – Europe 23:100510Row Supplementary Table 4 | – | Not from SCAN: cancer registry data for England, 2012–2018, from a peer-reviewed study. It shows that the stage at diagnosis is linked to survival; it does not measure delay itself. |
| Five-year survival, pancreatic NET found at stage 4 | 26% | people with pancreatic NET in England, 2012–2018 (cancer registry) | Five-year survival, pancreatic NET, stage 4 at diagnosis (unadjusted) | White et al. (2022), The Lancet Regional Health – Europe 23:100510Row Supplementary Table 4 | – | Not from SCAN: cancer registry data for England, 2012–2018, from a peer-reviewed study. It shows that the stage at diagnosis is linked to survival; it does not measure delay itself. |
| Neuroendocrine Cancer UK's published average time to diagnosis from first symptom | 4.5 years | published number; the source survey had 303 respondents | 'On average it takes 4.5 years to be diagnosed from the first symptom'Wording as asked or published. | Neuroendocrine Cancer UK, The invisible cancer (February 2026)Row – | – | Not from SCAN: Neuroendocrine Cancer UK's published average, from a survey of 303 people published in 2018 (Basuroy et al., BMC Cancer), run with the NET Patient Foundation. SCAN's UK average of 4.7 years covers only respondents first told they had something else, so the two measure different things. |
4. Who opened the door
| Number | Value | Base | Question | Source and row | Compared with | Caveat |
|---|---|---|---|---|---|---|
| A GP suggested the test that led to diagnosis | 20.8% | 341 UK respondents | DA2, who suggested the test that led to your NET diagnosis (single choice): GP | SCAN 2025Row 325 (base 324) | Global 19.5% (n=2,764); Europe 19.7% (n=1,566) | Describes the UK respondents who chose to answer, not all UK patients. Similar to the Global share; iNCA's tables do not mark the UK as different from the global number. |
| An emergency physician suggested the test that led to diagnosis | 12.0% | 341 UK respondents | DA2, who suggested the test that led to your NET diagnosis (single choice): emergency physician | SCAN 2025Row 329 (base 324) | Global 8.1% (n=2,764); Europe 6.9% (n=1,566) | Describes the UK respondents who chose to answer, many reached through Neuroendocrine Cancer UK, not all UK patients. Global includes the UK. INCA's tables mark where a country differs from the global number, without naming the test. |
| A GP or an emergency physician suggested the test that led to diagnosis | 32.8% | 341 UK respondents | DA2, who suggested the test that led to your NET diagnosis (single choice): GP plus emergency physician | SCAN 2025Row 325 + 329 (summed) | – | Only one answer was allowed, so the two shares can be added. Describes the UK respondents who chose to answer, not all UK patients.Derived. |
| A surgeon suggested the test that led to diagnosis | 19.1% | 341 UK respondents | DA2, who suggested the test that led to your NET diagnosis (single choice): surgeon | SCAN 2025Row 355 (base 324) | Global 13.0% (n=2,764); Europe 13.5% (n=1,566) | Describes the UK respondents who chose to answer, not all UK patients. SCAN does not say how people came to see the specialist. |
| A gastroenterologist suggested the test that led to diagnosis | 15.2% | 341 UK respondents | DA2, who suggested the test that led to your NET diagnosis (single choice): gastroenterologist | SCAN 2025Row 337 (base 324) | Global 18.0% (n=2,764); Europe 17.8% (n=1,566) | Describes the UK respondents who chose to answer, not all UK patients. SCAN does not say how people came to see the specialist. |
5. Being heard (interim)
Not SCAN. Interim results from Neuroendocrine Cancer UK's diagnosis survey · 225 respondents · export 6 October 2026 · numbers will change
| Number | Value | Base | Question | Source and row | Compared with | Caveat |
|---|---|---|---|---|---|---|
| Respondents to NCUK's diagnosis survey at the interim export | 225 | 225 respondents to the interim export | Respondent count, interim export of 6 October 2026 | NCUK diagnosis survey (interim, export 6 Oct 2026)Row – | – | Interim results from Neuroendocrine Cancer UK's own diagnosis survey, not SCAN: 225 self-selected respondents at 6 October 2026, unweighted. The survey is open until December 2026, so the numbers will change.Interim. |
| Felt symptoms or experiences were dismissed or underestimated because they 'look well', constantly or regularly | 76.1% | 169 of 222 people who answered this question (interim) | Q104: felt symptoms or experiences dismissed or underestimated because you 'look well' (constantly 44.6%, regularly 31.5%) | NCUK diagnosis survey (interim, export 6 Oct 2026)Row Q104 (CSV column 442) | – | The question does not say by whom. Interim, unweighted results from Neuroendocrine Cancer UK's own diagnosis survey, not SCAN; the survey is open until December 2026, so the numbers will change.Interim. |
| Rated the experience from first symptom to diagnosis good or better | 49.1% | 108 of 220 people who answered both rating questions (interim) | Q98: overall experience from first symptom to confirmed diagnosis (good, very good or excellent) | NCUK diagnosis survey (interim, export 6 Oct 2026)Row Q98 (CSV column 423) | – | A looking-back rating from the same 220 people who rated their experience since diagnosis. Interim, unweighted results from Neuroendocrine Cancer UK's own diagnosis survey, not SCAN; the survey is open until December 2026, so the numbers will change.Interim. |
| Rated their experience since diagnosis good or better | 74.5% | 164 of 220 people who answered both rating questions (interim) | Q99: your experience since diagnosis to the present day (good, very good or excellent) | NCUK diagnosis survey (interim, export 6 Oct 2026)Row Q99 (CSV column 425) | – | A looking-back rating of experience since diagnosis, from the same 220 people who rated the road to diagnosis (74.4% of the 223 who answered this question alone). Interim, unweighted results from Neuroendocrine Cancer UK's own diagnosis survey, not SCAN; the survey is open until December 2026, so the numbers will change.Interim. |
6. What the name brings
| Number | Value | Base | Question | Source and row | Compared with | Caveat |
|---|---|---|---|---|---|---|
| Saw a NET clinical nurse specialist in the past 12 months | 61.3% | 341 UK respondents, past 12 months | T11, services used in the past 12 months: clinical nurse specialist in NETs | SCAN 2025Row 1644 (base 1643) | Global 27.6% (n=2,764); Global excluding the UK about 22.9% (n=2,423); Europe 32.0% (n=1,566); Australia 52.3% (n=197); New Zealand 50.0% (n=110); Denmark 60.0% (n=40) | Among the highest of the countries compared with 100 or more respondents, and iNCA's tables mark the UK above the global number. It describes who answered as much as UK services, since people connected to Neuroendocrine Cancer UK may be over-represented, and more than one answer was allowed.More than one answer allowed. |
| Saw a NET specialist in the past 12 months | 59.8% | 341 UK respondents, past 12 months | T11, services used in the past 12 months: NET specialist | SCAN 2025Row 1656 (base 1643) | Global 57.2% (n=2,764); Europe excluding the UK about 67.0% (n=1,225) | In the middle of the 17 countries compared. More than one answer allowed.More than one answer allowed. |
| Had a multidisciplinary team (MDT) in the past 12 months | 51.3% | 341 UK respondents, past 12 months | T11, services used in the past 12 months: multidisciplinary team | SCAN 2025Row 1648 (base 1643) | Global 35.6% (n=2,764) | Describes the UK respondents who chose to answer, not all UK patients. More than one answer allowed. INCA's tables mark the UK above the global number.More than one answer allowed. |
| Used none of the listed services in the past 12 months | 7.6% | 341 UK respondents, past 12 months | T11, services used in the past 12 months: none of these | SCAN 2025Row 1664 (base 1643) | Global 16.1% (n=2,764) | Describes the UK respondents who chose to answer, many reached through Neuroendocrine Cancer UK, not all UK patients. Global includes the UK. INCA's tables mark where a country differs from the global number, without naming the test.More than one answer allowed. |
7. Keeping the case moving
| Number | Value | Base | Question | Source and row | Compared with | Caveat |
|---|---|---|---|---|---|---|
| Lack of experts for a first or second opinion, past 12 months | 13.5% | 341 UK respondents, past 12 months | T18, issues in the past 12 months: lack of experts to give a first or second opinion | SCAN 2025Row 1531 (base 1512) | Global 17.1% (n=2,764) | From the same question as the delays, and in line with the Global share; iNCA's tables do not mark the UK as different from the global number. More than one answer allowed.More than one answer allowed. |
| No coordination issues at all, past 12 months | 34.6% | 341 UK respondents, past 12 months | T18, issues in the past 12 months: no issues at all | SCAN 2025Row 1539 (base 1512) | Global 41.1% (n=2,764) | Describes the UK respondents who chose to answer, not all UK patients. One option in a question where more than one answer was allowed.More than one answer allowed. |
| Named slow case documentation as the single issue to address first | 17.3% | 341 UK respondents | T19_1, the one major issue to address (single choice): slow processing of case documentation | SCAN 2025Row 1601 (base 1596) | Global 7.2% (n=2,764) | One choice per person from all 341 respondents, including those who reported no issues. Among the highest of the countries compared, with others close behind. INCA's tables mark the UK above the global number. |
| MDT meetings on their case not frequent enough, past 12 months | 22.3% | 341 UK respondents, past 12 months | T18, issues in the past 12 months: multidisciplinary team meetings not frequent enough | SCAN 2025Row 1519 (base 1512) | Global 12.0% (n=2,764) | Describes the UK respondents who chose to answer, not all UK patients. More than one answer allowed. INCA's tables mark the UK above the global number.More than one answer allowed. |
| Delays in receiving medical professionals' opinions, past 12 months | 24.9% | 341 UK respondents, past 12 months | T18, issues in the past 12 months: delays in receiving medical professionals' opinions | SCAN 2025Row 1527 (base 1512) | Global 15.2% (n=2,764) | Describes the UK respondents who chose to answer, not all UK patients. More than one answer allowed. INCA's tables mark the UK above the global number.More than one answer allowed. |
8. What would help
| Number | Value | Base | Question | Source and row | Compared with | Caveat |
|---|---|---|---|---|---|---|
| More healthcare professionals knowledgeable in NETs would help most | 72.1% | 341 UK respondents | A5, what would help most with the ongoing management of your NET: more healthcare professionals knowledgeable in NETs | SCAN 2025Row 3002 | Global 56.4% (n=2,764); Global excluding the UK about 54.2% (n=2,423) | More than one answer allowed, and it is not known whether choices were capped. The order of answers within the UK is more reliable than the level compared with other countries. INCA's tables mark the UK above the global number.More than one answer allowed. |
| More information brochures from NET professionals would help most | 10.3% | 341 UK respondents | A5, what would help most: more information brochures from NET professionals | SCAN 2025Row 3008 | Global 11.6% (n=2,764) | More than one answer allowed. Read as people coming ahead of leaflets, not as information not mattering: 27.3% report issues with access to information.More than one answer allowed. |
9. Who answered
| Number | Value | Base | Question | Source and row | Compared with | Caveat |
|---|---|---|---|---|---|---|
| Respondents who are patients | 93.3% | 341 UK respondents | S1, patient or carer: patient | SCAN 2025Row 12 | Global 85.2% (n=2,764) | Describes the UK respondents who chose to answer, many reached through Neuroendocrine Cancer UK, not all UK patients. Global includes the UK. INCA's tables mark where a country differs from the global number, without naming the test. |
| Respondents who are family, partner or friend carers | 6.7% | 341 UK respondents | S1, patient or carer: family member, partner or friend carer | SCAN 2025Row 14 | Global 14.7% (n=2,764) | About 23 people, who answered about the patient they care for. Describes the UK respondents who chose to answer, many reached through Neuroendocrine Cancer UK. |
| Patient is female | 78.0% | 341 UK respondents (carers answered for the patient) | S4, gender of the patient: female | SCAN 2025Row 27 | Global 63.1% (n=2,764); Europe 61.7% (n=1,566) | Of all 341 respondents; carers gave the patient's gender. The 2019 survey asked the question differently, so its share (64.2%) is not a like-for-like match. |
| Average age of patients | 60.4 | 341 UK respondents | S5, age of the patient: mean | SCAN 2025Row 51 | Global 58.5 (n=2,764) | Age at the time of the survey, not at diagnosis. Describes the UK respondents who chose to answer, not all UK patients. |
| Patients aged 60 or over | 55.7% | 341 UK respondents | S5, age of the patient: 60–69 (33.1%) plus 70 and over (22.6%) | SCAN 2025Row 46 + 48 | Global 50.6% (n=2,764) | Age at the time of the survey, not at diagnosis. Worked out by adding two age bands.Derived. |
| Stage 4 at diagnosis (self-reported) | 36.4% | 341 UK respondents | T2.1, do you know the stage of your disease at the time of diagnosis: stage IV | SCAN 2025Row 892 (base 883) | Global 24.2% (n=2,764) | Self-reported; 30.2% of respondents did not know their stage. Given to describe who answered, not as a finding: people with later-stage disease may be more likely to find a charity and answer. INCA's tables mark the UK above the global number. In the 2019 survey, a different group of people, it was 20.4%. |
| In their first two years since diagnosis (years 0 and 1) | 30.5% | 341 UK respondents | Years since diagnosis: 0 and 1 | SCAN 2025Row 265 + 267 | Europe 22.8% (n=1,566) | The UK respondents are newer to diagnosis than Europe's, which can affect how they rate their experience. Worked out by adding two answers.Derived. |
| Used a patient support group in the past 12 months | 48.1% | 341 UK respondents, past 12 months | T11, services used in the past 12 months: patient support group | SCAN 2025Row 1652 (base 1643) | Global 29.6% (n=2,764) | High support-group use partly reflects how people were reached for the survey, and helps explain why the UK respondents look as they do. More than one answer allowed.More than one answer allowed. |
| 2019 survey: told they had at least one other condition before neuroendocrine cancer | 53.0% | 148 of 279 UK respondents to the 2019 survey | DA6, same wording and answer options as 2025 (codes 1 and 2); 2025 number 51.9% of 341 | SCAN 2019Row 2019 file rows 253 + 254 (base 252) | – | The same question asked in 2019 of a different group of people, six years earlier. A comparison between two surveys, not a trend. The 2025 group is more often female (78.0% against 64.2%) and more often stage 4 at diagnosis (36.4% against 20.4%).Derived. |
| 2019 survey: no coordination issues at all, past 12 months | 45.5% | 279 UK respondents to the 2019 survey | T18, same wording, options and base as 2025; 2025 number 34.6% of 341 | SCAN 2019Row 2019 file row 596 | – | The same question asked in 2019 of a different group of people, so a comparison between two surveys, not a trend. More than one answer allowed. The 2025 group is more often female (78.0% against 64.2%) and more often stage 4 at diagnosis (36.4% against 20.4%).More than one answer allowed. |
The 17 countries compared
Full-sample SCAN 2025 respondents per country. In the charts, a country point resting on fewer than 100 answers to that question is drawn hollow, and one standing for fewer than 10 people, or leaving fewer than 10 on the other side, is left off.
| Country | Respondents |
|---|---|
| United States | 360 |
| United Kingdom | 341 |
| Germany | 255 |
| China | 223 |
| Australia | 197 |
| Netherlands | 172 |
| France | 158 |
| Taiwan | 148 |
| Italy | 142 |
| Sweden | 121 |
| New Zealand | 110 |
| Ireland | 104 |
| Norway(under 100) | 93 |
| Belgium(under 100) | 62 |
| Denmark(under 100) | 40 |
| Canada(under 100) | 37 |
| Japan(under 100) | 35 |